Insmed's brensocatib (Brinsupri) has received FDA approval as the first treatment for non-cystic fibrosis bronchiectasis, a chronic lung condition affecting approximately 500,000 Americans. Brensocatib, a dipeptidyl peptidase 1 (DPP-1) inhibitor, works by targeting neutrophilic inflammation, addressing the root cause of bronchiectasis exacerbations. The approval followed positive Phase 3 data demonstrating the drug’s ability to reduce respiratory exacerbations and improve patients' quality of life. Insmed plans to commercialize Brinsupri in the U.S., with ongoing regulatory filings for approval in Europe, the UK, and Japan. The product represents a potential multibillion-dollar growth driver for Insmed.